Literature DB >> 12798133

SNAREs and epithelial cells.

Thomas Weimbs1, Seng Hui Low, Xin Li, Geri Kreitzer.   

Abstract

SNARE proteins control the membrane fusion events of membrane trafficking pathways. Work in epithelial cells has shown that polarized trafficking to the apical and basolateral plasma membrane domains requires different sets of SNAREs, suggesting a mechanism that contributes to the overall specificity of polarized trafficking and, perhaps, the formation and maintenance of polarity itself. This article describes methods that have been designed and adapted specifically for the investigation of SNAREs in epithelial cells. The knowledge of the subcellular localization of a SNARE of interest is essential to understand its function. Unfortunately, the endogenous expression levels of SNAREs are often low which makes detection challenging. We provide guidelines for determination of the localization of SNAREs by immunofluorescence microscopy including methods for signal amplification, antigen retrieval, and suppression of antibody cross-reactivity. To define which trafficking pathway a SNARE of interest is involved in, one needs to specifically inhibit its function. We provide guidelines for SNARE inhibition by overexpression of the SNARE of interest. An alternative is to introduce inhibitors of SNARE function, such as antibodies or clostridial toxins, into cells. Two methods are presented to make this possible. The first allows the monitoring of effects on trafficking pathways by biochemical assays, and is based on plasma membrane permeabilization using the bacterial toxin streptolysin-O. The second is suitable for single-cell observations and is based on microinjection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12798133     DOI: 10.1016/s1046-2023(03)00025-2

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  7 in total

1.  The membrane-associated protein, supervillin, accelerates F-actin-dependent rapid integrin recycling and cell motility.

Authors:  Zhiyou Fang; Norio Takizawa; Korey A Wilson; Tara C Smith; Anna Delprato; Michael W Davidson; David G Lambright; Elizabeth J Luna
Journal:  Traffic       Date:  2010-03-17       Impact factor: 6.215

Review 2.  Potential pharmacological interventions in polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Robert W Schrier
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.

Authors:  Jonathan M Shillingford; Noel S Murcia; Claire H Larson; Seng Hui Low; Ryan Hedgepeth; Nicole Brown; Chris A Flask; Andrew C Novick; David A Goldfarb; Albrecht Kramer-Zucker; Gerd Walz; Klaus B Piontek; Gregory G Germino; Thomas Weimbs
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

4.  The cytoplasmic domain of proEGF negatively regulates motility and elastinolytic activity in thyroid carcinoma cells.

Authors:  Aleksandra Glogowska; Janette Pyka; Astrid Kehlen; Marek Los; Paul Perumal; Ekkehard Weber; Sheue-yann Cheng; Cuong Hoang-Vu; Thomas Klonisch
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

5.  Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.

Authors:  Jonathan M Shillingford; Klaus B Piontek; Gregory G Germino; Thomas Weimbs
Journal:  J Am Soc Nephrol       Date:  2010-01-14       Impact factor: 10.121

6.  Soluble syntaxin 3 functions as a transcriptional regulator.

Authors:  Adrian J Giovannone; Christine Winterstein; Pallavi Bhattaram; Elena Reales; Seng Hui Low; Julie E Baggs; Mimi Xu; Matthew A Lalli; John B Hogenesch; Thomas Weimbs
Journal:  J Biol Chem       Date:  2018-02-23       Impact factor: 5.157

7.  The SNARE Protein Syntaxin 3 Confers Specificity for Polarized Axonal Trafficking in Neurons.

Authors:  Linda Soo Hoo; Chris D Banna; Carolyn M Radeke; Nikunj Sharma; Mary E Albertolle; Seng Hui Low; Thomas Weimbs; Carol A Vandenberg
Journal:  PLoS One       Date:  2016-09-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.